Title: MiRNA-374b-5p and miRNA-106a-5p are related to inflammatory bowel disease via
regulating IL-10 and STAT3 signaling pathways
Version: 7 Date: 06 Sep 2022
Reviewer:  Mojtaba Shohan
Reviewer's report:
Comments to the authors
Pre-translational and post-translational modifications are recognized as one of the most
important pathways regulating the expression and secretion of many targeted genes and proteins
which are involved in inflammatory diseases progression. As cytoplasmic regulators, MiRNAs
are recently have been given full attention to be used in biomarker-based diagnosis, treatment
strategies and patients follow up in many cancers and inflammatory diseases. According to
the latest reports in the literature, MiRNA-374b-5p and MiRNA-106-5p are dual functional
non-coding small RNAs that are significantly involved in tumor suppressing (non-small cells
lung cancer), tumor metastasis and invasion (gastric cancer cells), pro-inflammatory function
in vascular thrombosis (by suppressing IL-10 expression), anti-inflammatory effects in obesity
and insulin resistance regulation, and actually plays as a regulator of inflammation in IBDs
patients. So far, we know that the IL-10/STAT3 axis is considerably involved in IBDs related
inflammation. Interestingly, for the first time Dongjie Li et.al are reporting novel findings in this
paper regarding the relation between IL-10/STAT3 axis and MiRNA-374b-5p/MiRNA-106-5p
upregulation and inhibition in IBDs patients. By performing various laboratory analyses
such as western blotting, flow cytometry, qRT-PCR relative gene expression evaluation,
bioinformatic analysis and DLR assay Dongjie et.al are clearly demonstrating the central
role of MiRNA-374b-5p/MiRNA-106-5p in the regulation of IL-10/STAT3 mediated anti-
inflammatory effects in IBDs. In my opinion, good writing, exact analysis and grouping the
samples, integrity of the text and well-discussed results are the features of this paper and it could
be added to the literature as an opening window followed by the next researches clarifying more
evidences regarding the topic. There are few minor revisions that is recommended to the authors
before publication. Here are my minor concerns:
1- In the caption of table 1, please give brief definition about the disease classifications for UC
and CD patients.  E1/E2/E3 for UC and L1 to L4 for CD patients.
2- It is recommended to the authors that evaluate the expression of this MiRNAs in colonic
biopsies of IBDs patients in the next publications.
best regards.
Title: MiRNA-374b-5p and miRNA-106a-5p are related to inflammatory bowel disease via
regulating IL-10 and STAT3 signaling pathways
Version: 7 Date: 06 Sep 2022
Reviewer:  Mojtaba Shohan
Reviewer's report:
Comments to the authors
Pre-translational and post-translational modifications are recognized as one of the most
important pathways regulating the expression and secretion of many targeted genes and proteins
which are involved in inflammatory diseases progression. As cytoplasmic regulators, MiRNAs
are recently have been given full attention to be used in biomarker-based diagnosis, treatment
strategies and patients follow up in many cancers and inflammatory diseases. According to
the latest reports in the literature, MiRNA-374b-5p and MiRNA-106-5p are dual functional
non-coding small RNAs that are significantly involved in tumor suppressing (non-small cells
lung cancer), tumor metastasis and invasion (gastric cancer cells), pro-inflammatory function
in vascular thrombosis (by suppressing IL-10 expression), anti-inflammatory effects in obesity
and insulin resistance regulation, and actually plays as a regulator of inflammation in IBDs
patients. So far, we know that the IL-10/STAT3 axis is considerably involved in IBDs related
inflammation. Interestingly, for the first time Dongjie Li et.al are reporting novel findings in this
paper regarding the relation between IL-10/STAT3 axis and MiRNA-374b-5p/MiRNA-106-5p
upregulation and inhibition in IBDs patients. By performing various laboratory analyses
such as western blotting, flow cytometry, qRT-PCR relative gene expression evaluation,
bioinformatic analysis and DLR assay Dongjie et.al are clearly demonstrating the central
role of MiRNA-374b-5p/MiRNA-106-5p in the regulation of IL-10/STAT3 mediated anti-
inflammatory effects in IBDs. In my opinion, good writing, exact analysis and grouping the
samples, integrity of the text and well-discussed results are the features of this paper and it could
be added to the literature as an opening window followed by the next researches clarifying more
evidences regarding the topic. There are few minor revisions that is recommended to the authors
before publication. Here are my minor concerns:
1- In the caption of table 1, please give brief definition about the disease classifications for UC
and CD patients.  E1/E2/E3 for UC and L1 to L4 for CD patients.
2- It is recommended to the authors that evaluate the expression of this MiRNAs in colonic
biopsies of IBDs patients in the next publications.
best regards.
Please review this paper.
user
Title: MiRNA-374b-5p and miRNA-106a-5p are related to inflammatory bowel disease via
regulating IL-10 and STAT3 signaling pathways
Version: 7 Date: 06 Sep 2022
Reviewer:  Mojtaba Shohan
Reviewer's report:
Comments to the authors
Pre-translational and post-translational modifications are recognized as one of the most
important pathways regulating the expression and secretion of many targeted genes and proteins
which are involved in inflammatory diseases progression. As cytoplasmic regulators, MiRNAs
are recently have been given full attention to be used in biomarker-based diagnosis, treatment
strategies and patients follow up in many cancers and inflammatory diseases. According to
the latest reports in the literature, MiRNA-374b-5p and MiRNA-106-5p are dual functional
non-coding small RNAs that are significantly involved in tumor suppressing (non-small cells
lung cancer), tumor metastasis and invasion (gastric cancer cells), pro-inflammatory function
in vascular thrombosis (by suppressing IL-10 expression), anti-inflammatory effects in obesity
and insulin resistance regulation, and actually plays as a regulator of inflammation in IBDs
patients. So far, we know that the IL-10/STAT3 axis is considerably involved in IBDs related
inflammation. Interestingly, for the first time Dongjie Li et.al are reporting novel findings in this
paper regarding the relation between IL-10/STAT3 axis and MiRNA-374b-5p/MiRNA-106-5p
upregulation and inhibition in IBDs patients. By performing various laboratory analyses
such as western blotting, flow cytometry, qRT-PCR relative gene expression evaluation,
bioinformatic analysis and DLR assay Dongjie et.al are clearly demonstrating the central
role of MiRNA-374b-5p/MiRNA-106-5p in the regulation of IL-10/STAT3 mediated anti-
inflammatory effects in IBDs. In my opinion, good writing, exact analysis and grouping the
samples, integrity of the text and well-discussed results are the features of this paper and it could
be added to the literature as an opening window followed by the next researches clarifying more
evidences regarding the topic. There are few minor revisions that is recommended to the authors
before publication. Here are my minor concerns:
1- In the caption of table 1, please give brief definition about the disease classifications for UC
and CD patients.  E1/E2/E3 for UC and L1 to L4 for CD patients.
2- It is recommended to the authors that evaluate the expression of this MiRNAs in colonic
biopsies of IBDs patients in the next publications.
best regards.
assistant